M. Frieman

SARS-CoV-2 ORF8 modulates lung inflammation and clinical disease progression

This study shows that SARS-CoV-2 ORF8 protein modulates lung inflammation and disease severity in mice by affecting macrophage infiltration and function.

CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replication in vitro and in vivo

This paper identifies CNP as a novel antiviral target that inhibits SARS-CoV-2 replication by blocking mitochondrial depolarization and mPTP activation in vitro and in vivo.

Diet Induced Obesity and Diabetes Enhance Mortality and Reduces Vaccine Efficacy for SARS-CoV-2

This study shows that obesity and diabetes increase SARS-CoV-2 mortality and reduce vaccine efficacy in mice, with neutrophil depletion improving outcomes.

A neonatal mouse model characterizes transmissibility of SARS-CoV-2 variants and reveals a role for ORF8

This study establishes a neonatal mouse model to study SARS-CoV-2 transmissibility, showing variant differences in infectious shedding and identifying ORF8's role in transmission.

SARS-CoV-2 Variant Spike and accessory gene mutations alter pathogenesis

This study investigates how non-Spike mutations in SARS-CoV-2 variants affect pathogenesis and transmission, revealing that accessory gene mutations can lead to attenuating phenotypes.

Self-assembling short immunostimulatory duplex RNAs with broad spectrum antiviral activity

This paper introduces self-assembling short duplex RNAs that induce interferon production and inhibit multiple respiratory viruses.

Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infection

The paper screens 18,000 drugs for antiviral activity against SARS-CoV-2, identifies synergistic combinations of pyrimidine biosynthesis inhibitors and nucleoside analogs, and validates their efficacy in vitro and in vivo.

Immunogenicity and In vivo protection of a variant nanoparticle vaccine that confers broad protection against emerging SARS-CoV-2 variants

This study evaluates a nanoparticle vaccine against SARS-CoV-2 variants, showing it induces strong immune responses and protection in mice and baboons against multiple variants.

Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity

This study evaluates AH:CpG adjuvant's ability to enhance RBD vaccine efficacy in aged mice and human elder cells, showing strong neutralizing antibody responses and cytokine production.

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination

This study shows that NVX-CoV2373 vaccine induces antibodies with both neutralizing and Fc-effector functions, which together provide maximal protection against SARS-CoV-2 in non-human primates.

Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail

This paper determines the structures of two antibodies in the AZD7442 cocktail that neutralize SARS-CoV-2 and identifies critical residues for neutralization and viral escape.

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms

This study evaluates the in vitro antiviral activity of three Ebola and Marburg virus inhibitors against SARS-CoV-2 and explores their potential mechanisms of action.

Functional Landscape of SARS-CoV-2 Cellular Restriction

This study identifies key interferon stimulated genes (ISGs) that restrict SARS-CoV-2 infection by inhibiting viral entry, RNA synthesis, and release.

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19

This study identifies PF-00835321 as a potent inhibitor of SARS-CoV-2 3CL protease with in vitro antiviral activity and clinical evaluation potential.

Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics

This paper demonstrates the use of human organ chips to rapidly repurpose therapeutics for viral pandemics, identifying amodiaquine as a potential treatment for SARS-CoV-2.

Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo

This study evaluates 20 FDA-approved drugs for antiviral activity against SARS-CoV-2 and SARS-CoV, finding 17 inhibit SARS-CoV-2 at non-cytotoxic concentrations and two protect mice from SARS-CoV disease.